ESMO26: Sac-TMT’s OptiTROP-Lung04 survival gain holds, putting the onus on MSD
In the Phase III OptiTROP-Lung04 trial, sac-TMT extended median OS to 25.9 months in EGFR-mutated NSCLC.
Comment & Opinion
IDWeek 2026: novel antifungal turletricin demonstrates positive Phase II results
IDWeek 2026: olorofim shows promise in second-line invasive aspergillosis
ESMO26: Amgen’s Imdelltra posts win in first-line SCLC maintenance setting
ESMO26: An $8.4bn bispecific ADC doubles PFS in HR+/HER2- breast cancer
ESMO26: Oral cell cycle inhibitors place Cyclin E1 as new target in PROC
New evidence shows depression linked to circadian rhythm
Influenza mortality in hospitalised patients affected by vaccination
